Mozenavir

Mozenavir (DMP 450) is an orally active and highly selective inhibitor of HIV-1 protease (Ki=0.3 nM) . Mozenavir blocks the cleavage and processing of viral polyproteins, inhibiting the replication and maturation of HIV-1. Mozenavir is promising for research of HIV infection[1][2][3].

Product Specifications

CAS Number

[174391-92-5]

Product Name Alternative

DMP-450

UNSPSC

12352005

Target

HIV; HIV Protease

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Field of Research

Infection

Smiles

O[C@H]([C@H]([C@H](N(C1=O)CC2=CC(N)=CC=C2)CC3=CC=CC=C3)O)[C@@H](CC4=CC=CC=C4)N1CC5=CC(N)=CC=C5

Molecular Formula

C33H36N4O3

Molecular Weight

536.66

References & Citations

[1]Mamidala E, et al. In silico prediction of mozenavir as a potential drug for SARS-CoV-2 infection via binding multiple drug targets. Saudi J Biol Sci. 2022 Feb;29 (2) :840-847.|[2]Karpoormath R, et al. Novel PCU cage diol peptides as potential targets against wild-type CSA HIV-1 protease: synthesis, biological screening and molecular modelling studies[J]. Medicinal Chemistry Research, 2013, 22: 3918-3933.|[3]Hodge CN, et al. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996 Apr;3 (4) :301-14.